Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Trial of Inhaled Mosliciguat in Pulmonary Hypertension Associated with Interstitial Lung Disease
jRCT2051240306Phase 2Recruiting
- Sponsor
- Pulmovant
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing Mosliciguat arm with Placebo / delayed-start mosliciguat arm (2 arms). Primary endpoint: Percent change from baseline in pulmonary vascular resistance (PVR) at Week 16. Started Mar 2025; status: recruiting.
02
Drugs
mosliciguat
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on jRCT2051240306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240306.